Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Understanding Sickle Cell Disease: Epidemiology, Treatment, and Market Outlook

      Research_and_Markets_Logo

      News provided by

      Research and Markets

      Nov 22, 2023, 11:45 ET

      Share this article

      Share this article


      DUBLIN , Nov. 22, 2023 /PRNewswire/ -- The "US Sickle Cell Disease - Market Insight, Epidemiology And Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

      Sickle cell disease (SCD) is a genetic blood disorder characterized by abnormal hemoglobin, leading to complications such as chronic pain, organ damage, and increased susceptibility to infections. The primary cause of SCD is a mutation in the HBB gene, affecting hemoglobin production. Individuals with SCD inherit two copies of the mutated gene, leading to abnormal red blood cells that obstruct blood flow and cause sickle cell crises.

      Treatment options for SCD include Hydroxyurea, NSAIDs, blood transfusions, chelating agents, nutritional supplements, and broad-spectrum antibiotics. Approved therapies include ENDARI (L-glutamine oral powder), ADAKVEO (crizanlizumab-tmca), and OXBRYTA (voxelotor). Promising investigational therapies include Exa-cel (Vertex Pharmaceuticals/CRISPR Therapeutics), Inclacumab (Global Blood Therapeutics/Pfizer), and Etavopivat (Forma Therapeutics/Novo Nordisk).

      The total prevalent cases of SCD trait in the US were approximately 4,284,000 in 2022 and are projected to increase by 2032. The market for SCD in the US is estimated to be around USD 700 million in 2022.

      Despite the complexities of SCD, advancements in treatment approaches and ongoing research efforts offer hope for improved management and potential cures. Enhancing healthcare services, raising awareness, and supporting individuals with SCD are essential steps toward addressing the challenges associated with this disease.

      The "US Sickle Cell Disease Market Insight, Epidemiology, and Market Forecast - 2032" report offers extensive knowledge regarding epidemiology segments and predictions, providing insights into potential future growth in diagnosis rates, disease progression, and treatment guidelines. It includes comprehensive insights into the current management techniques and emerging therapies, as well as detailed analysis of the SCD market's historical and projected market size (2019-2032), market share of therapies, and underlying rationale.

      Key players in the SCD treatment landscape include Novartis Pharmaceuticals, Global Blood Therapeutics/Pfizer, Emmaus Life Sciences, Vertex Pharmaceuticals/CRISPR Therapeutics, Forma Therapeutics/Novo Nordisk, Bluebird Bio, and more.

      Sickle Cell Disease (SCD) Drug Chapters

      The report provides in-depth evaluations of marketed therapies and late-stage pipeline drugs related to SCD, offering valuable information on clinical trials, pharmacological mechanisms, designations, approval status, patent information, and pros and cons associated with each drug. It also presents the latest news updates and press releases on drugs targeting SCD.

      Market Outlook

      The treatment goals for SCD aim to relieve pain, prevent infections, and manage complications. The report highlights different approaches, both pharmacologic and nonpharmacological, for managing SCD, including hydroxyurea, ENDARI (L-glutamine), ADAKVEO (crizanlizumab), and OXBRYTA (voxelotor), as well as cognitive behavioral therapy, biofeedback, relaxation techniques, acupuncture, and hypnosis.

      Epidemiology and Patient Population

      The report provides insights into the epidemiology of SCD in the United States, including total prevalent cases of SCD trait, total prevalent cases of SCD, diagnosed cases of SCD, age-specific prevalence, and type-specific prevalence from 2019 to 2032. It reveals that the total prevalent cases of SCD trait in the US are projected to increase, with diagnosed cases estimated at approximately 100,000 cases in 2022.

      KOL Views and Qualitative Analysis

      To ensure the latest trends are captured, the report includes insights from Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) from various hospitals and universities. This qualitative analysis, including SWOT analysis and Conjoint Analysis, provides a comprehensive understanding of the SCD market and treatment landscape.

      Market Access and Reimbursement

      The report delves into market access and reimbursement scenarios in the United States, examining the cost-effectiveness of approved therapies, programs that enhance accessibility and affordability, and insights on patients insured under federal or state government prescription drug programs.

      Sickle Cell Disease (SCD) Report Insights

      • Patient Population
      • Therapeutic Approaches
      • SCD Market Size and Trends
      • Existing Market Opportunity

      Sickle Cell Disease (SCD) Report Key Strengths

      • Ten-Year Forecast
      • The United States Coverage
      • SCD Epidemiology Segmentation
      • Key Cross Competition

      Sickle Cell Disease (SCD) Report Assessment

      • Current Treatment Practices
      • Unmet Needs
      • Market Attractiveness
      • Qualitative Analysis (SWOT, Conjoint Analysis)

      Key Questions Answered

      • Will there be changes in the treatment approach to cater to older SCD patients, as over 50% of them belong to the older age group?
      • Are there improvements in pain management recommendations for SCD?
      • Will research and development advances lead to future tests and therapies for SCD?
      • How will diagnostic testing impact the treatment landscape of SCD?
      • What uptake will new therapies witness in the coming years for SCD patients?

      A selection of companies mentioned in this report includes

      • Vertex Pharmaceuticals
      • CRISPR Therapeutics
      • Bluebird Bio
      • Global Blood Therapeutics
      • Pfizer
      • Agios Pharmaceuticals
      • Editas Medicine
      • Forma Therapeutics
      • Novo Nordisk
      • Bausch Health

      For more information about this report visit https://www.researchandmarkets.com/r/woyazh

      About ResearchAndMarkets.com
      ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

      Media Contact:

      Research and Markets
      Laura Wood, Senior Manager
      [email protected] 

      For E.S.T Office Hours Call +1-917-300-0470
      For U.S./CAN Toll Free Call +1-800-526-8630
      For GMT Office Hours Call +353-1-416-8900

      U.S. Fax: 646-607-1907
      Fax (outside U.S.): +353-1-481-1716

      Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

      SOURCE Research and Markets

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.